Application of transjugular liver biopsy in the diagnosis and treatment of complicated and severe liver diseases
-
摘要:
目的 探讨经颈静脉肝穿刺活检(TJLB)在疑难重症肝病诊断及治疗中应用的意义。 方法 回顾性分析2016年1月-2021年5月在解放军总医院第五医学中心接受TJLB的31例患者的临床资料,对穿刺的适应证、成功率、最终诊断结果进行分析。 结果 31例患者中男15例,女16例。8例因肝衰竭凝血机制障碍、13例因肝硬化合并腹水、10例因肝硬化合并血小板减少(<50×109/L)不宜行经皮肝穿刺活检,符合实施TJLB适应证。TJLB穿刺成功率100%,穿刺条数2~4条。无严重不良事件。患者出院明确诊断26例(83.87%)。其中特发性门静脉高压5例,药物性肝衰竭或肝硬化9例,自身免疫性肝病5例,其他原因肝硬化或肝衰竭7例,尚不能明确病因者5例,此外,为证实诊断及决策是否肝移植患者3例。 结论 TJLB在疑难重症肝病诊治中发挥重要作用,但尚有一定局限性,临床上应注意筛选适宜患者实施。 Abstract:Objective To investigate the application value of transjugular liver biopsy (TJLB) in the diagnosis and treatment of complicated and severe liver diseases. Methods A retrospective analysis was performed for the clinical data of 31 patients who underwent TJLB in The Fifth Medical Center of Chinese PLA General Hospital, including indication for puncture, success rate, and final diagnosis. Results Among the 31 patients, there were 15 male patients and 16 female patients. Percutaneous liver biopsy was unsuitable for 8 patients with liver failure and disturbances of blood coagulation, 13 with liver cirrhosis and ascites, and 10 with liver cirrhosis and thrombocytopenia (< 50×109/L), which were the indications for TJLB. The success rate of TJLB puncture was 100%, with 2-4 passes for puncture. No serious adverse event was observed. Of all 31 patients, 26 (83.87%) had a definite diagnosis at discharge, among whom there were 5 patients with idiopathic portal hypertension, 9 patients with drug-induced liver failure or liver cirrhosis, 5 patients with autoimmune liver disease, and 7 patients with liver cirrhosis or liver failure due to other causes, and 5 patients had unknown etiology. In addition, 3 patients underwent biopsy to confirm the diagnosis and decision of whether liver transplantation should be performed. Conclusion TJLB plays an important role in the diagnosis and treatment of complicated and severe liver diseases and still has certain limitations, and therefore, suitable patients should be selected in clinical practice. -
Key words:
- Liver Diseases /
- Biopsy, Needle /
- Diagnosis /
- Therapeutics
-
表 1 患者相关化验指标
指标 数值 Alb(g/L) 33.00(28.00~37.00) ALT(U/L) 33.00(18.00~63.00) AST(U/L) 49.00(35.00~140.00) ALP(U/L) 149.00(84.00~266.00) GGT(U/L) 98.00(27.00~156.00) TBil(μmol/L) 57.30(18.10~164.60) PTA(%) 52.90(42.90~70.60) INR 1.37(1.13~1.58) WBC(×109/L) 3.38(2.14~5.30) Hb(g/L) 105.00(93.00~124.00) PLT(×109/L) 68.00(47.00~118.00) 注:数据描述方式为M (P25~P75)。 -
[1] BRAVO AA, SHETH SG, CHOPRA S. Liver biopsy[J]. N Engl J Med, 2001, 344(7): 495-500. DOI: 10.1056/NEJM200102153440706. [2] DOHAN A, GUERRACHE Y, BOUDIAF M, et al. Transjugular liver biopsy: Indications, technique and results[J]. Diagn Interv Imaging, 2014, 95(1): 11-15. DOI: 10.1016/j.diii.2013.08.009. [3] CADRANEL JF, NOUSBAUM JB, GOUILLOU M, et al. Major changes in the number and indications of liver biopsy for chronic liver diseases over one decade in France[J]. Eur J Gastroenterol Hepatol, 2016, 28(9): e26-e32. DOI: 10.1097/MEG.0000000000000683. [4] LYU S, YOU SL, YU Q, et al. Feasibility and significance of transjugular liver biopsy in diagnosis and treatment of complicated and severe liver diseases: A single-center analysis of 5 cases[J]. Chin J Hepatol, 2017, 25(10): 772-774. DOI: 10.3760/cma.j.issn.1007-3418.2017.10.011.吕飒, 游绍莉, 余强, 等. 经颈静脉肝穿刺活组织检查在疑难重症肝病诊治中的可行性及意义: 单中心5例患者分析[J]. 中华肝脏病杂志, 2017, 25(10): 772-774. DOI: 10.3760/cma.j.issn.1007-3418.2017.10.011. [5] CRAWFORD AR, LIN XZ, CRAWFORD JM. The normal adult human liver biopsy: A quantitative reference standard[J]. Hepatology, 1998, 28(2): 323-331. DOI: 10.1002/hep.510280206. [6] YOU SL, ZHU B, RONG YH, et al. Diagnosis analysis of 9453 cases with liver diseases[J]. Chin J Health Care Med, 2012, 14(6): 459-462. DOI: 10.3969/j.issn.1674-3245.2012.06.017.游绍莉, 朱冰, 荣义辉, 等. 9453例待查肝病的诊断分析[J]. 中华保健医学杂志, 2012, 14(6): 459-462. DOI: 10.3969/j.issn.1674-3245.2012.06.017. [7] BERNAL W, WENDON J. Acute liver failure[J]. N Engl J Med, 2013, 369(26): 2525-2534. DOI: 10.1056/NEJMra1208937. [8] YOU S, RONG Y, ZHU B, et al. Changing etiology of liver failure in 3, 916 patients from northern China: A 10-year survey[J]. Hepatol Int, 2013, 7(2): 714-720. DOI: 10.1007/s12072-013-9424-5. [9] European Association for the Study of the Liver. EASL clinical practice guidelines: Vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202. DOI: 10.1016/j.jhep.2015.07.040. [10] KHANNA R, SARIN SK. Non-cirrhotic portal hypertension-diagnosis and management[J]. J Hepatol, 2014, 60(2): 421-441. DOI: 10.1016/j.jhep.2013.08.013. [11] REN Y, ZHENG SJ. Progress of idiopathic portal hypertension[J]. Chin J Gastroenterol Hepatol, 2019, 28(6): 708-710. DOI: 10.3969/j.issn.1006-5709.2019.06.025.任艳, 郑素军. 特发性门脉高压研究现状[J]. 胃肠病学和肝病学杂志, 2019, 28(6): 708-710. DOI: 10.3969/j.issn.1006-5709.2019.06.025. [12] MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065. [13] ZHAO LH, JIA JD. Etiological diagnosis and standard treatment of portal hypertension should be taken seriously[J]. J Clin Hepatol, 2019, 35(1): 10-12. DOI: 10.3969/j.issn.1001-5256.2019.01.001.赵连晖, 贾继东. 应重视门静脉高压症的病因诊断及规范治疗[J]. 临床肝胆病杂志, 2019, 35(1): 10-12. DOI: 10.3969/j.issn.1001-5256.2019.01.001. [14] Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS), Minimally Invasive Intervention Collaborative Group, Chinese Society of Gastroenterology, Emergency Intervention Committee, Chinese College of Interventionalists, et al. Consensus on clinical application of hepatic venous pressure gradient in China (2018)[J]. J Clin Hepatol, 2018, 34(12): 2526-2536. DOI: 10.3969/j.issn.1001-5256.2018.12.008.中国门静脉高压诊断与监测研究组(CHESS), 中华医学会消化病学分会微创介入协作组, 中国医师协会介入医师分会急诊介入专业委员会, 等. 中国肝静脉压力梯度临床应用专家共识(2018版)[J]. 临床肝胆病杂志, 2018, 34(12): 2526-2536. DOI: 10.3969/j.issn.1001-5256.2018.12.008. [15] ROCKEY DC, CALDWELL SH, GOODMAN ZD, et al. Liver biopsy[J]. Hepatology, 2009, 49(3): 1017-1044. DOI: 10.1002/hep.22742. [16] BEHRENS G, FERRAL H. Transjugular liver biopsy[J]. Semin Intervent Radiol, 2012, 29(2): 111-117. DOI: 10.1055/s-0032-1312572. [17] BEHRENS G, FERRAL H, GIUSTO D, et al. Transjugular liver biopsy: Comparison of sample adequacy with the use of two automated needle systems[J]. J Vasc Interv Radiol, 2011, 22(3): 341-345. DOI: 10.1016/j.jvir.2010.10.012. 期刊类型引用(12)
1. 张玉婷,施欢,李虤,沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 . 百度学术
2. 杜乔慧,吴克俭,王争争. GP73、GPR对慢性乙型肝炎患者肝硬化的诊断价值. 胃肠病学和肝病学杂志. 2022(07): 758-763 . 百度学术
3. 鲁荣华. 血清IL-2和IL-10对重度慢性乙型肝炎患者糖皮质激素治疗预后的评估价值. 中国卫生工程学. 2020(01): 83-85 . 百度学术
4. 毛桂芸,张永飞,郭延生,陶金忠. 山楂对围产期奶牛肝功能和血脂的影响. 中国奶牛. 2020(08): 36-39 . 百度学术
5. 陈晓玲,宋倩. 剪切波弹性成像和γ-谷氨酰转肽酶/血小板比用于诊断慢性乙型肝炎患者肝纤维化. 中国医学影像技术. 2020(10): 1499-1503 . 百度学术
6. 黄春明,杨湛,聂玉强,胡中伟,周永健,詹远京,郭家伟,余卫华. FibroScan联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化的初步探讨. 临床肝胆病杂志. 2019(02): 334-337 . 本站查看
7. 张小磊. 血清ALT、AST、GGT、HBV-DNA联合检测在慢性乙型肝炎病情评估中的应用. 内蒙古医学杂志. 2019(02): 211-212 . 百度学术
8. 尹国云. 瞬时弹性超声检测对蒙古族地区慢性乙型病毒性肝炎患者抗病毒治疗临床指导意义的研究. 世界复合医学. 2019(06): 90-92+114 . 百度学术
9. 黄春明,胡中伟,聂玉强,周永健,詹远京,郭家伟,余卫华. 无创诊断模式预测慢性乙型肝炎合并非酒精性脂肪肝患者肝纤维化的价值. 胃肠病学和肝病学杂志. 2019(08): 915-918 . 百度学术
10. 黄春明,杨湛,聂玉强,胡中伟,周永健,詹远京,郭家伟,余卫华. GGT/PLT比值对广东地区慢性乙型肝炎患者肝纤维化分期的预测价值. 临床肝胆病杂志. 2018(06): 1204-1208 . 本站查看
11. 李曼,李涛,刘振杰,曹永坚,钟伟国,余婷玉,何敏,徐宁. 以血清学指标比值为变量的肝纤维化诊断模型构建与评价. 山东医药. 2018(18): 17-20 . 百度学术
12. 李曼,张军,李涛,罗强,钟伟国,李嘉胜,徐宁. ADA/PLT、ALP/PLT比值对肝纤维化的诊断价值. 中国实验诊断学. 2017(11): 1923-1926 . 百度学术
其他类型引用(3)
-